AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Gilbert Lynn Marks received a stock grant of 3,775 shares of Common Stock on April 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and carry a grant price of $0.00 per share.
All 3,775 shares vest immediately, meaning Marks has full ownership without a vesting schedule. Following this award, he directly holds a total of 79,084 shares of AN2 Therapeutics common stock. This is a compensation-related grant, not an open-market purchase.
AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of common stock as part of non-employee director compensation. She acquired 1,192 shares at a price of $0.00 per share, issued in lieu of cash fees, and now directly holds 18,097 shares. According to the disclosure, all of the awarded shares vest immediately.
AN2 Therapeutics filed a shelf registration to offer up to $300,000,000 of securities and registered resale of up to 14,035,104 shares of common stock by selling securityholders. The filing carries forward $209,983,747.80 of unsold securities from an earlier registration and includes an $80,000,000 at-the-market sales agreement with Jefferies.
The prospectus states the company will not receive proceeds from resales by the selling securityholders and that any issuer sales under the sales agreement will be on a continuous, market-driven basis. The prospectus supplements will specify exact terms, proceeds treatment and any selling-holder identities.
AN2 Therapeutics, Inc. entered an Open Market Sale Agreement with Jefferies that allows it to issue and sell, from time to time, up to $80 million of its common stock through at-the-market offerings under a Form S-3 shelf registration.
Jefferies will act as sales agent and receive a commission of up to 3.0% of gross proceeds. On the same date, AN2 terminated its prior TD Cowen at-the-market program, under which it had already sold 2,502,000 shares for aggregate proceeds of $20,016,251.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported a repricing and replacement of stock options on March 19, 2026. She received new stock option grants covering 73,665, 66,000 and 82,300 shares of common stock, each with a $3.91 per-share exercise price, matching the issuer’s closing price that day.
On the same date, options over identical share amounts with higher exercise prices of $6.596, $17.28 and $14.29 were disposed of back to the company. One grant is fully vested, while two grants vest monthly in forty‑eight equal installments starting from March 25, 2022 and January 1, 2023, contingent on continued service. The $3.91 exercise price may revert to the original higher price if the options are exercised or service ends before a defined "Premium End Date."
AN2 Therapeutics, Inc. Chief Development Officer Sanjay Chanda reported compensation-related option changes, not open-market trades. On March 19, 2026, three existing stock option awards were repriced so that each now has an exercise price of $3.91 per share, matching the closing common stock price on the repricing date.
Each repriced award covers stock options to buy common stock in amounts of 66,000, 57,950 and 41,665 shares. The filing shows matching dispositions of the prior higher‑priced options back to the issuer. One option is fully vested, while the others vest monthly over 48 months starting March 25, 2022 and January 1, 2023, subject to continuous service.
The new $3.91 exercise price can revert to the original higher exercise price if, before the "Premium End Date", the repriced options are exercised or employment ends. The Premium End Date is the earliest of September 19, 2027, a change in control, or the reporting person's death or disability.
AN2 Therapeutics director Gilbert Lynn Marks reported a repricing of stock options with no open-market trades in common shares. On March 19, 2026, he acquired several new stock option awards covering common stock at an exercise price of $3.91 per share and simultaneously disposed of older options back to the issuer for the same share amounts.
The footnotes state that $3.91 represents the closing price of AN2 Therapeutics’ common stock on the repricing date and that the options are fully vested. The exercise price will revert to the original higher exercise price if the repriced options are exercised or if his service ends before the defined “Premium End Date.”
AN2 Therapeutics director Aziz Kabeer reported a repricing of stock options. On March 19, 2026, he received two grants of stock options for 20,724 and 23,742 shares of common stock, each with a new exercise price of $3.91 per share, matching the closing market price that day.
At the same time, he disposed of the same numbers of older options back to the company that had higher exercise prices of $17.28 and $5.91 per share. The repriced options are fully vested and remain subject to a "Premium End Date" that can cause the exercise price to revert to the original level if certain events occur before September 19, 2027.
AN2 Therapeutics director Patricia A. Martin reported a repricing of several stock options on March 19, 2026. She disposed of three existing options to purchase 24,999, 10,362 and 23,742 shares of common stock at exercise prices of $6.596, $17.28 and $5.91 per share, respectively, and received new, fully vested options for the same share amounts at an exercise price of $3.91 per share.
According to the board-approved terms, the $3.91 exercise price equals the closing stock price on the repricing date and will revert to each option’s original exercise price if the repriced option is exercised or her service ends before the “Premium End Date,” defined as the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Margaret M. FitzPatrick reported a board-approved repricing of stock options on the company’s common stock. On March 19, 2026, existing options were surrendered to the issuer and replaced with new fully vested options covering the same number of shares at an exercise price of $3.91 per share.
The repricing keeps all other terms unchanged, except that the exercise price will revert to the original higher level if the repriced options are exercised, or if her service ends, before the “Premium End Date.” The Premium End Date is the earliest of September 19, 2027, a change in control, or her death or disability.